• 1. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 2. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 3. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 4. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 5. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726

Chemical Profile of (R)-(+)-1-(2-PYRROLIDINYLMETHYL)PIPERIDINE (CAS No. 575469-26-0)

The compound (R)-(+)-1-(2-pyrrolidinylmethyl)piperidine, identified by its CAS number 575469-26-0, is a significant molecule in the field of pharmaceutical chemistry and drug development. This chiral piperidine derivative has garnered attention due to its unique structural properties and potential applications in medicinal chemistry. The presence of a pyrrolidinylmethyl side chain attached to a piperidine core introduces specific steric and electronic characteristics that make this compound a valuable scaffold for designing novel therapeutic agents.

In recent years, the demand for enantiomerically pure compounds has surged, particularly in the development of biologically active molecules where stereochemistry plays a crucial role in efficacy and safety. The (R)-configuration of this compound, as indicated by the prefix (R)-(+), suggests that it is the levorotatory enantiomer, which often exhibits distinct pharmacological properties compared to its racemic counterpart. This specificity is particularly important in drug design, where the wrong enantiomer can lead to reduced efficacy or even adverse effects.

The structural motif of (R)-(+)-1-(2-pyrrolidinylmethyl)piperidine finds relevance in several pharmacophoric frameworks. Piperidine derivatives are well-known for their role in central nervous system (CNS) drugs, due to their ability to cross the blood-brain barrier and interact with various neurotransmitter receptors. The pyrrolidinylmethyl group further enhances the compound's potential by introducing additional hydrogen bonding capabilities and spatial constraints, which can be exploited to fine-tune binding interactions with biological targets.

Current research in medicinal chemistry increasingly focuses on developing molecules with enhanced selectivity and reduced side effects. The chiral center in (R)-(+)-1-(2-pyrrolidinylmethyl)piperidine provides a strategic point for modulating pharmacokinetic and pharmacodynamic properties. Studies have shown that such piperidine-based scaffolds can be modified to target a wide range of therapeutic areas, including but not limited to antipsychotics, antidepressants, anticonvulsants, and analgesics.

One of the most compelling aspects of this compound is its potential as a building block for more complex drug candidates. Researchers have leveraged similar piperidine derivatives in the synthesis of small-molecule inhibitors that disrupt critical biological pathways involved in diseases such as cancer, inflammation, and neurodegeneration. The flexibility offered by the piperidine ring allows for the introduction of various substituents at different positions, enabling chemists to tailor the molecule's properties to specific biological needs.

Advances in computational chemistry have further accelerated the design and optimization process for compounds like (R)-(+)-1-(2-pyrrolidinylmethyl)piperidine. Molecular modeling techniques enable researchers to predict how different structural modifications will affect binding affinity and metabolic stability. This high-throughput virtual screening approach has been instrumental in identifying promising candidates for further experimental validation.

In clinical settings, the development of next-generation therapeutics often hinges on understanding how molecular structure influences drug behavior. The pyrrolidinylmethyl group in this compound contributes to its lipophilicity, which is a key factor determining its distribution within the body. By optimizing this balance between lipophilicity and polarizability, drug developers can enhance oral bioavailability and target specificity.

Additionally, the chirality of (R)-(+)-1-(2-pyrrolidinylmethyl)piperidine raises interesting questions about enantioselective metabolism. Enzymes in the liver and other tissues often exhibit preferences for specific enantiomers, leading to differential clearance rates. Understanding these metabolic pathways is crucial for predicting drug interactions and designing drugs with improved pharmacokinetic profiles.

Recent publications have highlighted the utility of piperidine derivatives in addressing unmet medical needs. For instance, modifications to this core structure have been explored in the development of novel antiviral agents targeting RNA-dependent RNA polymerases. The ability to fine-tune steric hindrance around the piperidine ring has allowed researchers to create molecules that bind tightly to viral proteins while sparing host enzymes.

Another area where this compound shows promise is in neurodegenerative diseases. Piperidine-based ligands have been investigated for their potential to modulate cholinergic systems, making them candidates for treating conditions such as Alzheimer's disease. The pyrrolidinylmethyl group provides an excellent platform for developing acetylcholinesterase inhibitors or other agents that can enhance cognitive function without significant side effects.

The synthesis of (R)-(+)-1-(2-pyrrolidinylmethyl)piperidine also exemplifies modern synthetic strategies employed in pharmaceutical research. Asymmetric synthesis methods allow for the efficient production of enantiomerically pure compounds without resorting to laborious separation techniques. Catalytic processes using transition metals have enabled cleaner reactions with higher yields, reducing waste and improving sustainability.

Looking ahead, the future applications of this compound are likely to expand as new therapeutic targets are discovered and validated. Its versatility as a scaffold suggests that it could play a role across multiple therapeutic areas, from oncology to infectious diseases. Collaborative efforts between academia and industry will be essential in translating these early findings into viable clinical candidates.

• 100158-63-2(2-(Pyrrolidin-1-ylmethyl)piperidine)
• 112906-37-3(1-[(pyrrolidin-2-yl)methyl]piperidine)
• 5298-72-6((1-Methylpiperidin-2-yl)methanamine)
• 26116-12-1((1-ethylpyrrolidin-2-yl)methanamine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)